Zydus Lifesciences Limited — Others, 21-01-2025: Action(s) taken or orders passed

German Remedies Pharmaceuticals Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited, has received a Demand Order imposing a penalty of ₹1.66 crore related to alleged excess availment of Input Tax Credit (ITC) for the financial year 2018-19. The company plans to contest this order through an appeal. While there is no material financial impact expected, this situation underscores regulatory scrutiny that could raise operational risks. Investors may view the move as a neutral impact, given the company's stance to challenge the penalty and its minimal immediate financial implications.